Entegris Demonstrates Cold Chain Solutions for Life Sciences Applications at BioProcess International 2021

Entegris to showcase expertise from longstanding experience in semiconductor industry to address challenges in delivering cold chain products and scaling up gene and cell therapy supply chains.

News Release
Download PDF (187.3 kB)

Billerica, MA, September 16, 2021 – Entegris, Inc. (NASDAQ: ENTG), a world-class supplier of advanced materials and process solutions for the semiconductor and other high-technology industries, today announced that the company will showcase its life sciences cold chain solutions for bulk drug substance and cell banking along with a comprehensive set of bag solutions, motion bioreactor bags, mixing systems, and microcarrier separation systems at Booth #745 at the BioProcess International 2021 conference. The event will take place at the Boston Convention and Exhibition Center and virtually September 20 – 23.

Muhammad Siddiqui, life science cold chain application engineer at Entegris, will present on Wednesday, September 22 at 2:30 p.m. about current manufacturing challenges, maintaining the integrity of drug products throughout the development and distribution process, and ensuring yields and cost-efficiencies as volume production of biologics scale up. This presentation will explain the importance of material selection, review the characteristics of a scalable material-focused solution for storage and low-temperature operations, and identify materials that may be suitable for further evaluation in specific gene therapy applications.

“As a leader in advanced materials science, we are especially proud of our Aramus™ 2D assembly line and are eager to exhibit it at BPI this year,” says John Lynch, vice president of Life Sciences at Entegris. “We believe they are among the cleanest and most robust assemblies on the market and deliver impressive results in increased purity and yield.”

"We are thrilled that Entegris will be at BioProcess International 2021,” says Howard Choi, Event Marketing Manager of BioProcess International. “Entegris offers a unique perspective in advanced materials science as they help manufacturers in a variety of industries solve critical technology challenges to innovate faster and work more efficiently. Bioprocessing is certainly a complex industry with intricate supply chains and distinctive processes, and we think many of our attendees will be excited to learn how to apply Entegris’ best practices to their production.”

Entegris’ Aramus™ 2D bag assemblies have highly innovative attributes, which make them ideal for freezing, transporting, storing, and thawing drug substances, like COVID-19 vaccines. They are designed to be resistant to extreme cold temperatures and to withstand gamma sterilization. Many leading biopharma companies have expressed strong interest in using this innovation and several customers are currently incorporating it into their production.

To learn about how Entegris is supporting the life sciences sector, visit https://lifesciences.entegris.com/.

About Entegris
Entegris is a world-class supplier of advanced materials and process solutions for the semiconductor and other high-technology industries. Entegris has approximately 5,800 employees throughout its global operations and is ISO 9001 certified. It has manufacturing, customer service, and/or research facilities in the United States, Canada, China, France, Germany, Israel, Japan, Malaysia, Singapore, South Korea, and Taiwan. Additional information may be found at www.entegris.com.

Forward-Looking Statements
This news release contains forward-looking statements. The words “believe,” “expect,” “anticipate,” “intend,” “estimate,” “forecast,” “project,” “should,” “may,” “will,” “would” or the negative thereof and similar expressions are intended to identify such forward-looking statements. These forward-looking statements include statements related to Entegris’ presentation at the BioProcess International 2021 conference; applications for Entegris’ technologies; and other matters. These statements involve risks and uncertainties, and actual results may differ materially from those projected in the forward-looking statements. These risks and uncertainties include, but are not limited to, those risk factors and additional information described in Entegris’ filings with the Securities and Exchange Commission, including under the heading “Risk Factors” in Item 1A of Entegris’ Annual Report on Form 10-K for the fiscal year ended December 31, 2020, filed with the Securities and Exchange Commission on February 5, 2021, and in Entegris’ other periodic filings.

Media Contact:
Connie Chandler
Director of Corporate Communications
T +1 978-436-6546

Investor Contact:
Bill Seymour
VP of Investor Relations
T +1 952-556-1844